SOURCE: eLocity Inc.

June 21, 2005 07:20 ET

Tuesday's June 21st Stock Trading Alert

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by eLocity Inc.

SARASOTA, FL -- (MARKET WIRE) -- June 21, 2005 -- eLocity's stocks to watch for Tuesday are -- Xpention Genetics, Inc. (OTC BB: XPNG), ViroPharma Inc. (NASDAQ: VPHM), Transkaryotic Therapies, Inc. (NASDAQ: TKTX), Shire Pharmaceuticals (NASDAQ: SHPGY).

Investors, have a look at Xpention Genetics, Inc. (OTC BB: XPNG), a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans, as well as therapeutic vaccines and other treatment methods for companion animal cancers. The company issued a press release Monday announcing that it has signed a contract to develop an immunological cancer test for use on canines with AMC Cancer Center in Denver, Colorado, a nonprofit research institute dedicated to the prevention and control of cancer and other chronic diseases.

The cancer test will use Xpention's licensed p65 technology from the University of Texas MD Anderson Cancer Center, the company said. P65 is a promising genetic marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission, Xpention Genetics said, and added that levels of p65 also appear to have a direct correlation to tumor mass and size.

Xpention Genetics CEO, David Kittrell, commented that the collaboration with AMC Cancer Research Center is the first step in the development of a commercially viable cancer detection test for canines, and that he believes, "this immunological test for cancer in canines using the p65 marker will afford pet owners the opportunity to detect cancer in their companions much earlier, thus leading to more effective and potentially life saving treatments"

Shares of Xpention Genetics, Inc. (OTC BB: XPNG) are currently trading at around 89 cents a share.

Other stocks to watch:

ViroPharma Inc. (NASDAQ: VPHM)

Pharmaceutical company ViroPharma Inc. announced Monday that it would put into effect its right to convert $18.75 million principal amount of its 6% Convertible Senior Secured Notes due October 2009 into 7,500,000 shares of common stock. The company also announced the purchase of an additional $12.2 million of its outstanding 6% Convertible Subordinated Notes due March 2007.

VPHM closed Monday's regular trading session at $7.00, up 40 cents.

Transkaryotic Therapies, Inc. (NASDAQ: TKTX), Shire Pharmaceuticals (NASDAQ: SHPGY)

Transkaryotic Therapies announced positive top-line results Monday from its pivotal Phase III clinical trial evaluating its investigational human enzyme replacement therapy, iduronate-2-sulfatase (I2S), for the treatment of patients with Hunter syndrome, a rare, life-threatening genetic disorder. The company said that in the trial, patients who received 0.5 mg/kg of I2S on a weekly basis showed a statistically significant improvement in the primary efficacy endpoint compared to patients receiving placebo. Later this year, Shire Pharmaceuticals (NASDAQ: SHPGY) is slated to acquire Transkaryotic Therapies.

TKTX closed Monday's regular trading session at $36.60. SHPGY finished the session at $34.57.

About eLocity Inc: eLocity owns and operates three financial websites for investors.

-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.

-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast.

-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for newsletter and ad services for XPNG (Public Company). The compensation is one thousand dollars. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information

  • Contact:
    eLocity Inc.
    941-544-3498
    Thomas Clay